Regeneron Lobbying for its Database to be the Linchpin of Obama's Precision Medicine Program

Monday, May 18, 2015

Source: FierceBiotechIT

Regeneron Pharmaceuticals ($REGN) is lobbying for the exome sequencing database it is building with Geisinger Health System to become the linchpin of President Obama's Precision Medicine program. The idea is for a consortium of drugmakers to fund the database, giving Regeneron a way of clawing back some of its investment while waiting for long-term drug R&D bets to pay off.

Tarrytown, NY-based Regeneron hooked up with Geisinger in January 2014 to sequence the exomes of 250,000 people. The idea is to build a database from which Regeneron can uncover drug targets like PCSK9, the gene inhibited by its hotly-anticipated, Sanofi ($SNY)-partnered cholesterol drug. Regeneron began building the database to support its in-house R&D programs, but Reuters reports it is now interested in opening up access. The idea is to make the database a key component of the Precision Medicine program and have other drugmakers fund the work.

View All News »